Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 390 participants.
Also called NCT06788626
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 390 participants
- Registry
-
NCT06788626
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06788626. Randomized; single masking; primary purpose treatment. Start 2025-02 (anticipated); primary completion 2028-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment
- Acronym
- GALLOP2
- Condition
- Acute Ischemic Stroke
- Condition
- Large Vessel Occlusion
- Condition
- Neuroprotective Drugs
- Condition
- Endovascular Treatment
- Intervention (Drug)
- Semaglutide 0.5 mg
- Intervention (Other)
- Standard medical treatment
- Lead sponsor
- Wei Hu
- Collaborator
- Chinese University of Hong Kong
Record details
- Record id
cardio:ct-nct06788626- Content hash
163c27e84aab0a4ee6e16144287b65dd623956b7180c8eef4dab08e78a9b0e13